Urothelial Carcinoma Market

Market Overview:

The 7 major urothelial carcinoma markets are expected to exhibit a CAGR of 12.34% during 2024-2034.

The urothelial carcinoma market has been comprehensively analyzed in IMARC's new report titled "Urothelial Carcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Urothelial carcinoma, often refer to as transitional cell carcinoma, is a type of cancer that primarily originates in the urothelial cells lining the urinary tract. It majorly affects the bladder but can also occur in other parts of the urinary system, such as the renal pelvis, ureters, urethra, etc. The most common symptom is hematuria, that is the presence of blood in the urine. Various other indications can include frequent urination, a persistent urge to urinate, pain or discomfort during urination, pelvic or back pain, etc. The diagnosis of urothelial carcinoma typically begins with a thorough medical history assessment and physical examination. Several diagnostic procedures, such as urine analysis to detect blood or abnormal cells and imaging tests like ultrasound, computed tomography (CT) scan, magnetic resonance imaging (MRI), etc., to visualize the urinary tract and identify any abnormalities, are performed. A biopsy of suspicious areas is crucial for a definitive diagnosis, as it allows for microscopic examination of the tissue to confirm the presence of the ailment and determine the stage and grade of the tumor. Numerous additional tests, including imaging of the upper urinary tract and pelvic lymph nodes, may be conducted to assess the spread of the cancer.

The increasing cases of genetic mutations that disrupt the normal functioning of genes, thereby leading to uncontrolled cell growth and tumor development, are primarily driving the urothelial carcinoma market. In addition to this, the rising prevalence of several associated risk factors, such as tobacco use, exposure to aromatic amines, previous history of bladder cancer, chronic urinary tract infections, long-standing bladder inflammation, etc., is also creating a positive outlook for the market. Moreover, the emerging popularity of external beam radiation therapy for treatment, since it utilizes high-energy beams to target cancer cells and relieve symptoms as well as improve the quality of life in patients, is further bolstering the market growth. Apart from this, the inflating application of immune checkpoint inhibitors, such as pembrolizumab, atezolizumab, nivolumab, etc., which harness the body's immune system to attack cancer cells and offer increased response rates and durable responses, as compared to traditional chemotherapy, is acting as another significant growth-inducing factor. Additionally, the escalating usage of minimally invasive surgical techniques, including robotic-assisted and laparoscopic surgeries, on account of their several associated benefits, such as reduced blood loss, shorter hospital stays, improved surgical precision, etc., is expected to drive the urothelial carcinoma market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the urothelial carcinoma market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for urothelial carcinoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the urothelial carcinoma market in any manner.

Recent Developments:

• In June 2024, ALX Oncology Holdings Inc. presented findings from its Phase 1 ASPEN-07 clinical trial as a poster (abstract #4575) at the 2024 American Society of Cancer Oncology (ASCO) Annual Meeting. These findings represent the first evorpacept combination data with an antibody-drug conjugate from ASPEN-07's ongoing open-label, single-arm clinical trial of evorpacept in combination with PADCEV (enfortumab vedotin) in patients with locally advanced or metastatic urothelial carcinoma.
• In September 2023, Astellas Pharma Inc. and Seagen Inc. reported positive topline results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39) of PADCEV (enfortumab vedotin-ejfv) in combination with KEYTRUDA (pembrolizumab) versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer. Patients regardless of PD-L1 status who were eligible for carboplatin- or cisplatin-containing therapy for locally advanced or metastatic urothelial carcinoma and had not had prior treatment were recruited for the EV-302 trial.

Key Highlights:

• Urothelial carcinoma is the most common form of bladder cancer, accounting for almost 90% of all bladder cancer instances.
• The incidence of urothelial carcinoma is highest in people aged 70–90 years.
• In advanced nations like North America and Europe, bladder cancer is primarily urothelial.
• Smoking is related to nearly half of all bladder cancer instances. The risk of bladder cancer is estimated to be approximately two to four times higher for current smokers and three times higher for past smokers.
• Upper tract urothelial carcinoma occurs more frequently in men than in women, with a male-to-female ratio of 2:1.

Drugs:

BALVERSA (Erdafitinib) is a once-daily, oral FGFR kinase inhibitor approved by the FDA for the therapy of adults with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 mutations and has progressed during or after at least one line of platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

IPI 549 is a first-in-class oral immuno-oncology product candidate that targets tumor-associated myeloid cells by selectively inhibiting phosphoinositide-3-kinase-gamma (PI3K-gamma), lowering pro-tumor macrophage function while enhancing anti-tumor macrophage function. In preclinical investigations, IPI 549 revealed the capacity to transform macrophages from a pro-tumor (M2) immune suppressive role to an anti-tumor (M1) immune activating function, as well as to increase the action of checkpoint inhibitors and overcome resistance to them.

MV-NIS is under development by Vyriad for the treatment of urothelial carcinoma. The drug is intended to target cancer cells while sparing healthy cells. MV-NIS infects and kills cancer cells by releasing tumor antigens and inflammatory cytokines, resulting in a strong systemic and tumor-specific immune response.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the urothelial carcinoma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the urothelial carcinoma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current urothelial carcinoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the urothelial carcinoma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the urothelial carcinoma market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the urothelial carcinoma market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of urothelial carcinoma across the seven major markets?
• What is the number of prevalent cases (2018-2034) of urothelial carcinoma by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of urothelial carcinoma by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with urothelial carcinoma across the seven major markets?
• What is the size of the urothelial carcinoma patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of urothelial carcinoma?
• What will be the growth rate of patients across the seven major markets?
   

Urothelial Carcinoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for urothelial carcinoma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the urothelial carcinoma market?
• What are the key regulatory events related to the urothelial carcinoma market?
• What is the structure of clinical trial landscape by status related to the urothelial carcinoma market?
• What is the structure of clinical trial landscape by phase related to the urothelial carcinoma market?
• What is the structure of clinical trial landscape by route of administration related to the urothelial carcinoma market?